In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Amphenol's current price exceeds its PERT-weighted fair value by 19.1%, indicating potential overvaluation amid a wide valuation range and high downside risk (94.4%). Strong financial health contrasts with Monte Carlo median ($65.53) and base case ($78.19) well below market price. Valuation disparities reflect differing expectations on growth and risk.